Oslo Patient: Sibling Stem Cell Transplant Leads to Rare HIV Remission
In a significant development for HIV research, a man known as the “Oslo Patient” has maintained long-term remission of HIV following a stem cell transplant from his brother, who carries a rare genetic mutation that confers natural resistance to the virus. This case, first reported in 2020 and recently reaffirmed through sustained monitoring, represents one of only a handful of documented instances where HIV has been undetectable in the body without ongoing antiretroviral therapy (ART). While not a cure applicable to the broader population, the Oslo Patient’s experience offers critical insights into the mechanisms of HIV persistence and potential pathways toward functional remission.
Who Is the Oslo Patient?
The Oslo Patient is a man in his 30s from Norway who was diagnosed with HIV in 2008. He achieved viral suppression through standard antiretroviral therapy but later developed acute myeloid leukemia (AML), a aggressive form of blood cancer requiring intensive treatment. In 2018, he underwent an allogeneic hematopoietic stem cell transplant using donor cells from his younger brother.
Crucially, genetic testing revealed that the brother was heterozygous for the CCR5-Δ32 mutation — meaning he carried one copy of a genetic variant that alters the CCR5 co-receptor, which HIV uses to enter immune cells. Individuals with two copies of this mutation (homozygous) are highly resistant to HIV infection, while those with one copy may experience slower disease progression. The Oslo Patient’s brother did not have HIV but carried this protective trait.
How the Transplant Led to HIV Remission
The stem cell transplant replaced the Oslo Patient’s own immune system — including HIV-infected cells — with donor-derived cells. Although the donor was not fully resistant (having only one CCR5-Δ32 allele), the combination of several factors likely contributed to the sustained remission:
- Conditioning regimen: High-dose chemotherapy and radiation prior to transplant eliminated a significant portion of the patient’s existing immune cells, including HIV reservoirs.
- Graft-versus-host effect: The donor immune cells may have recognized and attacked residual HIV-infected cells in the recipient’s body.
- Reduced CCR5 expression: Even a single copy of the CCR5-Δ32 mutation in donor cells may have lowered the availability of functional CCR5 receptors, limiting HIV’s ability to infect new cells.
- Long-term immune reconstitution: Over time, the donor-derived immune system established itself without detectable HIV rebound, even after the patient discontinued ART in 2020 under medical supervision.
As of 2024, the Oslo Patient has remained in HIV remission for over four years without antiretroviral therapy, with no detectable virus in blood or tissue samples using highly sensitive assays. His case was formally documented in a 2021 case report published in Nature Medicine and has since been confirmed through ongoing clinical follow-up.
How Does This Compare to Other HIV ‘Cure’ Cases?
The Oslo Patient joins a small group of individuals who have achieved sustained HIV remission after stem cell transplantation, most notably:
- The Berlin Patient (Timothy Ray Brown): The first person considered cured of HIV, who received two transplants from a donor homozygous for CCR5-Δ32 in 2007 and 2008. He remained HIV-free until his death from leukemia in 2020.
- The London Patient: Achieved remission in 2019 after a stem cell transplant from a CCR5-Δ32 homozygous donor for Hodgkin’s lymphoma.
- The Düsseldorf Patient: Reported in 2020, also transplanted with CCR5-Δ32 homozygous cells and off ART since 2018.
- The New York Patient: A woman of mixed race who achieved remission in 2022 using umbilical cord blood stem cells partially matched and enriched for CCR5-Δ32, marking the first use of cord blood in such a case.
What distinguishes the Oslo Patient is that his donor was only heterozygous for CCR5-Δ32 — suggesting that complete genetic resistance may not be strictly necessary for remission, especially when combined with other immunological effects like graft-versus-host activity.
Why Isn’t This a Scalable Cure?
- High risk: The procedure carries a 5–15% mortality risk due to complications like graft-versus-host disease, infections, and organ toxicity.
- Donor scarcity: Fewer than 1% of people of Northern European descent are homozygous for CCR5-Δ32, and global diversity in the mutation is limited.
- Intensive treatment: Patients must undergo chemotherapy or radiation to suppress their own immune system before transplant.
- Availability: Stem cell transplants are reserved for life-threatening conditions like leukemia or lymphoma, not HIV alone.
As such, researchers view these cases not as a roadmap to widespread cure, but as proof-of-concept studies that reveal how HIV reservoirs can be reduced or controlled. The insights gained are informing next-generation strategies such as gene editing (e.g., CRISPR to disrupt CCR5), therapeutic vaccines, and broadly neutralizing antibodies aimed at achieving sustained remission without transplantation.
The Future of HIV Remission Research
The Oslo Patient’s case underscores the importance of studying rare events to understand HIV persistence. Scientists are now investigating:
- Whether early ART initiation limits reservoir size and improves chances of post-transplant remission.
- How modifier genes beyond CCR5 influence HIV control after immune reconstitution.
- Safe, non-transplant-based methods to mimic the graft-versus-host effect using immunotherapy.
- Long-term monitoring of immune function and viral reservoirs in remission patients to detect any risk of rebound.
Ongoing cohort studies, such as the IciStem consortium in Europe, continue to analyze outcomes from HIV-positive individuals undergoing stem cell transplants for cancer, aiming to refine criteria for predicting remission.
Key Takeaways
- The Oslo Patient achieved sustained HIV remission after a stem cell transplant from his brother, who carried one copy of the protective CCR5-Δ32 mutation.
- He has remained off antiretroviral therapy since 2020 with no detectable HIV, confirmed by sensitive testing.
- His case demonstrates that complete CCR5 resistance in the donor may not be required for remission, highlighting the role of graft-versus-host effects and conditioning regimens.
- While not scalable due to risks and donor limitations, such cases provide vital clues for developing safer, broader HIV cure strategies.
- Research continues into gene editing, immunotherapy, and therapeutic vaccines to induce remission without transplantation.
Frequently Asked Questions
Is the Oslo Patient considered cured of HIV?
Researchers describe his status as long-term remission or functional cure, meaning HIV is undetectable without treatment. However, due to the fact that the virus could theoretically persist at undetectable levels, the term “cure” is used cautiously. He is monitored regularly for any signs of viral rebound.
Can anyone with HIV get this treatment?
No. Stem cell transplants are only performed for life-threatening blood cancers or severe immune disorders, not HIV alone. The risks far outweigh benefits for people whose HIV is well-controlled with ART.
How rare is the CCR5-Δ32 mutation?
About 1% of people of Northern European descent are homozygous for CCR5-Δ32, and roughly 10–15% are heterozygous. The mutation is much rarer in African, Asian, and Indigenous populations.
What is the difference between a cure and remission in HIV?
A sterilizing cure would mean complete eradication of HIV from the body. Remission (or functional cure) means the virus is undetectable and not replicating without ART, though traces may remain. Most reported cases to date are considered remission rather than absolute eradication.
Are there safer alternatives being studied?
Yes. Approaches include using CRISPR to edit CCR5 in a patient’s own stem cells, therapeutic vaccines to boost immune control, and broadly neutralizing antibodies to suppress viral replication. These are in various stages of clinical testing.